Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/1057
Title: Effect of triptorelin on lower urinary tract symptoms in Australian prostate cancer patients.
Epworth Authors: Murphy, Declan
Grummet, Jeremy
Other Authors: Woo, Henry
Testa, Gerard
Chong, Michael
Stork, Andrew
Keywords: Lower Urinary Tract Symptoms
LUTS
International Prostate Symptom Score
IPSS
GnRH Agonist
ADT
Androgen Deprivation Therapy
Gonadotropin-Releasing Hormone
GnRH
Australian Prostate Cancer Research Centre, Epworth Healthcare, Richmond, VIC.
Issue Date: Feb-2017
Publisher: Dove Medical Press
Citation: Res Rep Urol. 2017 Feb 23;9:27-35
Abstract: PURPOSE: Prostate cancer is often comorbidly associated with lower urinary tract symptoms (LUTS), but few studies have assessed the effects of androgen deprivation therapy on LUTS in this patient group. PATIENTS AND METHODS: We conducted a prospective, noninterventional, multicenter, observational study to assess the effectiveness of triptorelin (11.25 mg every 12 weeks) over 48 weeks in men presenting with local stage T3/4 prostate cancer and moderate to severe LUTS (International Prostate Symptom Score [IPSS] >7) in a routine practice setting in Australia. RESULTS: Of the 44 men who enrolled, effectiveness data were available for 39 men. By the end of the study, 30% of men no longer met the IPSS criteria for moderate to severe LUTS. The proportion of patients with moderate to severe LUTS was 69.6% (16/23) at week 48 and 76.9% (30/39) at the last available visit (coprimary outcomes). An IPSS reduction of ≥3 from week 0 was observed in 47% of men at week 4, 56% at week 24, 61% (14/23) at week 48, and 61.5% (24/39) at the last available visit. Quality of life was rated as mostly satisfied-to-delighted by 39.5% of patients at week 0, 53.9% at week 24, and 77.3% at week 48. Triptorelin was well tolerated with 8 treatment-related adverse events reported, half of which were hot flushes; 5 patients discontinued due to the reported treatment-related adverse events. CONCLUSION: This observational study suggests that triptorelin improves moderate to severe LUTS in prostate cancer patients in a routine clinical practice setting.
URI: http://hdl.handle.net/11434/1057
DOI: 10.2147/RRU.S125791
URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5328125/pdf/rru-9-027.pdf
PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/28261572
ISSN: 2253-2447
Journal Title: Research and Report on Urology
Type: Journal Article
Affiliated Organisations: Sydney Adventist Hospital Clinical School, University of Sydney, Wahroonga, NSW.
Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC.
Department of Urology, Repatriation General Hospital, Daw Park, SA.
Type of Clinical Study or Trial: Prospective Observational Study
Appears in Collections:Cancer Services
UroRenal, Vascular
Epworth Prostate Centre

Files in This Item:
File Description SizeFormat 
effect of triptorelin on lower urinary tract.pdf666.44 kBAdobe PDFView/Open


Items in EKB are protected by copyright, with all rights reserved, unless otherwise indicated.